Isolated limb perfusion: The European experience

F. J. Lejeune, B. B R Kroon, F. Di Filippo, H. J. Hoekstra, M. Santinami, D. Liénard, A. M M Eggermont

Research output: Contribution to journalArticlepeer-review


More than 40 years after its design in the United States isolated limb perfusion is still a very promising and progressing technique. In Europe, very interesting developments have been made. The optimalization of the method, especially by using continuous leakage monitoring and using the drug melphalan, yielded good results in melanoma and the addition of TNF is the first demonstration of an active antiangiogenic treatment in the clinic. Furthermore, in sarcomas that are not amenable to surgery, ILP with TNF and melphalan represents a neoadjuvant treatment for limb-sparing surgery. Being a regional treatment ILP is not expected to significantly influence survival. This treatment modality is worthwhile to pursue in the local control of regionally advanced tumors, avoiding unnecessary mutilation.

Original languageEnglish
Pages (from-to)821-832
Number of pages12
JournalSurgical Oncology Clinics of North America
Issue number4
Publication statusPublished - 2001

ASJC Scopus subject areas

  • Oncology
  • Surgery


Dive into the research topics of 'Isolated limb perfusion: The European experience'. Together they form a unique fingerprint.

Cite this